Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30529263 | 0.78 | MIF (0.45) | DPP4 | |
| SCHEMBL1647830 | 0.78 | IDO1 (0.44) | — | |
| SCHEMBL1648243 | 0.78 | PSEN1 (0.40) | DPP4 | |
| SCHEMBL27424363 | 0.77 | NPC1 (0.33) | — | |
| SCHEMBL31397806 | 0.76 | HTT (0.36) | — | |
| SCHEMBL27429577 | 0.76 | TRPV4 (0.34) | — | |
| SCHEMBL7750833 | 0.75 | PYCR1 (0.46) | — | |
| SCHEMBL1647335 | 0.74 | RIPK1 (0.41) | DPP4 | |
| SCHEMBL6049 | 0.72 | TAAR1 (0.43) | — | |
| SCHEMBL7466318 | 0.72 | IDO1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190054-B1 | NONAQUEOUS ELECTROLYTE SOLUTION FOR SECONDARY BATTERY AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEM CORP (JP) | 2016-10-26 | — | — | EP | disclosed |
| US-20140127590-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION FOR SECONDARY BATTERY AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2014-05-08 | — | — | US | disclosed |
| US-8383629-B2 | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110136821-A1 | Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase Type 1 | VITAE PHARMACEUTICALS INC. | 2011-06-09 | — | — | US | disclosed |
| US-20110091768-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION FOR SECONDARY BATTERY AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
| EP-2265588-A1 | INHIBITORS OF 11ß -HYDROXYSTEROID DEHYDROGENASE TYPE 1 | Vitae Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2190054-A1 | NONAQUEOUS ELECTROLYTE SOLUTION FOR SECONDARY BATTERY AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | Mitsubishi Chemical Corporation (JP) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009108332-A1 | INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136821-A1 | Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase Type 1 | HSD11B1, HSD17B1, HSD3B1 | DPP4 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.